×
0.00405679513184594 0.0060953346855984 -0.00405679513184576 -0.00709939148073007 -0.0425963488843812 -0.0314503042596347 -0.0314503042596347 -0.0314503042596347
Stockreport

Protagonist Therapeutics Receives $1.34 Million SBIR Funding for Development of Biomarkers of IL-23 Receptor Antagonist Activity

PROTAGONIST THERAPEUTICS (PTGX)  More Company Research Source: PR Newswire
Last protagonist therapeutics earnings: 5/9 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.protagonist-inc.com
PDF NEWARK, Calif., May 24, 2017 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced the receipt of a Phase 2 Small Business Innovation Research (SBIR) Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH).  This award, Number 2R44DK104445-02, provides up to $1.34 million over two years to support research aimed at developing biomarkers that define IL-23 receptor (IL-23R) target engagement by oral peptide antagonists and the effects of that engagement on downstream signaling. Such biomarkers can be used for demonstrating early pharmacodynamics clinical proof-of-concept and estimating effective dose range for the treatment of inflammatory bowel diseases (IBD) with anti-IL-23R agents, including Protagonist's oral peptide drug candidate, PTG-200. The company expects to initiate human clinical testing of PTG-200 in the second half of 2017. Protagonist's research has sh [Read more]

IMPACT SNAPSHOT EVENT TIME: PTGX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS